Search results
Showing 406 to 420 of 493 results for weight management
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England.
Show all sections
- Overview
- Introduction
- Section A: Technologies suitable for evaluation using the evidence standards framework
- Section B: Classification of digital health technologies
- Section C: Evidence standards tables
- Terms used in the evidence standards framework
- How to meet the standards
- Section D: Early deployment standards for evidence-generation programmes
cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people...
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Medical technologies evaluation programme methods guide (PMG33)
Medical technologies evaluation programme methods guide
Show all sections
- 1 Introduction
- 2 The medical technologies evaluation programme
- 3 Selecting and routing technologies
- 4 Principles for developing medical technologies guidance
- 5 Scope
- 6 Evidence and expert advice
- 7 Evidence synthesis and cost-consequence analysis
- 8 Evaluation of the evidence and decision-making by the committee
Vertex retains all commercial and legal rights and discretions on the management of its activities which have been included in the...
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Stretta System for gastro-oesophageal reflux disease (MIB74)
NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .